Stay current with MiRXES
Keep up to date with our latest news and activities as we continue to innovate and develop our science and technology, bringing novel products to market. – from Singapore to the world.
Dr Holger Heyn, an expert in single-cell genomics and spatial transcriptomics, has joined the Scientific Advisory Board of MiRXES to help advance its development of RNA-powered multi-omics solutions for research and diagnosti
This new capital will support MiRXES’s growth as a global leader in cancer early detection tests and preventive healthcare
This study shows MiRXES qPCR profiling platform to be superior in reproducibility and detection rate compared to other commercial microRNA profiling platforms when used for validation of blood-based microRNA biomarkers.
A*STAR, TTSH and molecular diagnostic company MiRXES expand range of infectious disease testing solutions with the Fortitude SARS-CoV-2 & Flu A/B Test.
Collaborative study between MiRXES and Janseen shows microRNA-based biomarker signatures may support early identification and diagnosis of
Enhancing activities in Japan not only enable the easier and more accurate diagnosis of gastric cancer which is common case in Japan, but also help to propose the best medical and precision treatment for patients in Japan through their ultra-sensitive microRNA detection.
Stay informed and keep abreast with our media news.
8 Jul 2021
MiRXES has raised US$77 million in a Series C round, pushing to commercialise its early cancer detection test kits globally. This latest round values the biotech at over US$500 million and could pave the way for a public listing.
31 Mar 2021
This latest FT ranking of 500 of the region’s high-growth companies is compiled in partnership with Nikkei Asia and research provider Statista. MiRXES is ranked 194 position, and top 30 in Singapore.
Welcome to our knowledge base of insights in the frontiers of the biotech industry.
Across the many functional teams in MiRXES, from R&D to manufacturing and commercial, our women in science wear many different hats—to great success.
Media and Investor Contact
For media enquiries, please email: firstname.lastname@example.org